Get the Stockscreener App
51.23
1.65%
0.83
After Hours:
51.23
Qiagen Nv stock is traded at $51.23, with a volume of 1.27M.
It is up +1.65% in the last 24 hours and up +8.47% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$50.40
Open:
$50.86
24h Volume:
1.27M
Relative Volume:
0.92
Market Cap:
$10.91B
Revenue:
$1.98B
Net Income/Loss:
$83.59M
P/E Ratio:
136.98
EPS:
0.374
Net Cash Flow:
$502.31M
1W Performance:
+6.20%
1M Performance:
+8.47%
6M Performance:
+9.15%
1Y Performance:
+18.56%
1-Day Range:
$50.79
$51.58
1-Week Range:
$47.66
$51.58
52-Week Range:
$37.74
$51.58
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
51.23 | 10.91B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
475.03 | 176.18B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
202.81 | 141.70B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
549.97 | 43.48B | 3.93B | 894.97M | 837.70M | 10.82 |
|
IQV
Iqvia Holdings Inc
|
200.82 | 33.02B | 15.50B | 1.33B | 2.16B | 7.34 |
|
A
Agilent Technologies Inc
|
120.35 | 33.01B | 6.63B | 1.17B | 1.19B | 4.05 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen N.V.'s (NYSE:QGEN) high institutional ownership speaks for itself as stock continues to impress, up 4.3% over last week - Yahoo Finance
Berenberg raises Qiagen stock price target to EUR50 on growth pillars - Investing.com
What analysts say about Qiagen N.V. stockLightning-fast capital gains - Autocar Professional
What drives Qiagen N.V. stock priceHigh-velocity capital appreciation - Autocar Professional
Is Qiagen N.V. a good long term investmentRapid wealth creation - Autocar Professional
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels - BioSpace
BlackRock Discloses Significant Stake in Qiagen - AInvest
BlackRock’s Significant Stake in Qiagen Disclosed by AFM - TipRanks
Qiagen Announces Voting Rights Notification Involving BlackRock - TipRanks
QIAGEN launches long read sequencing panels for complex genomic analysis - StreetInsider
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. Stock Analysis and ForecastUnmatched profit growth - jammulinksnews.com
Qiagen NV stock reaches 52-week high at 48.91 USD - Investing.com India
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - Pressetext
BofA Securities Maintains Qiagen NV(QGEN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Qiagen Announces Significant Voting Rights Notification by BlackRock - TipRanks
Favorable Government Support Fuels Germany's Biotech Innovation and Commercialization: Market to Surpass USD 94 Billion by 2034 Led by QIAGEN, Thermo Fisher Scientific, Illumina and Roche - Yahoo.co
Qiagen N.V. (NYSE:QGEN) is favoured by institutional owners who hold 79% of the company - simplywall.st
Fivespan Said to Build Stake in Life Sciences Group Qiagen - MSN
Qiagen and Gencurix partner for oncology tests - MSN
Qiagen NV stock hits 52-week high at 48.82 USD By Investing.com - Investing.com South Africa
QIAGEN Announces Managerial Share Transaction - TipRanks
Qiagen NV stock hits 52-week high at 48.82 USD - Investing.com Australia
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast - Business Wire
QIAGEN NV : Deutsche Bank maintains a Buy rating - MarketScreener
Baptista Research Begins Qiagen Coverage at Hold - MarketScreener
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays - MSN
Qiagen N : announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2031 - MarketScreener
Qiagen N : announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2027 - MarketScreener
Qiagen N.V.(NYSE: QGEN) dropped from Russell 1000 Dynamic Index - MarketScreener
Ex-Dividend Reminder: Comcast, Qiagen and HA Sustainable Infrastructure Capital - Nasdaq
Qiagen Announces Managerial Share Transaction - TipRanks
Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships - MSN
QIAGEN Announces Election of Stephen Rusckowski as Chairman of S - GuruFocus
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):